Abstract
Background: Chemoradiotherapy for inoperable locally advanced pancreatic cancer has been in use at Weston Park Hospital since 2011 on the basis of the Selective Chemoradiation in Advanced Localized Pancreatic cancer (SCALOP) trial. Following induction chemotherapy if the tumour is either stable or responding, patients receive radiotherapy 50.4 gray in 28 fractions with concurrent capecitabine chemotherapy. We previously audited our outcomes in 2014 and determined concordance with the SCALOP trial outcomes. This audit is an expansion of the previous audit with double the sample size incorporating advances in treatments over time, besides extended follow up period. We aimed to obtain our survival outcomes, toxicity data and compare our results with the SCALOP clinical trial.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
